Posted On: 11/30/2014 2:08:47 PM
Post# of 63879
$CAPR
Will be watching
for that upside to unfold this way:
Capricor announced that the company’s lead
therapeutic candidate, CAP-1002, will be evaluated in an
additional indication, Duchenne Muscular Dystrophy (DMD).
The new program is based on preclinical data scheduled
for presentation at the American Heart Association’s
(AHA) Scientific Sessions on November 17.
We believe the new indication area, which expands
Capricor’s pipeline beyond the ischemic heart failure
market, represents an expansion of the company’s pipeline.
Website
On Low Floats Sticky
Shares Outstanding: 11.70M
Float: 3.39M
Will be watching
for that upside to unfold this way:
Capricor announced that the company’s lead
therapeutic candidate, CAP-1002, will be evaluated in an
additional indication, Duchenne Muscular Dystrophy (DMD).
The new program is based on preclinical data scheduled
for presentation at the American Heart Association’s
(AHA) Scientific Sessions on November 17.
We believe the new indication area, which expands
Capricor’s pipeline beyond the ischemic heart failure
market, represents an expansion of the company’s pipeline.
Website
On Low Floats Sticky
Shares Outstanding: 11.70M
Float: 3.39M
(0)
(0)
